Why Veeva Systems (VEEV) Is Up 7.5% After Major Pharma Firms Adopt Vault CRM Platform

• In recent weeks, Bristol Myers Squibb and several leading pharmaceutical companies announced adoption of Veeva Systems' Vault CRM platform to support their commercial operations.
• This wave of industry adoption highlights growing confidence in Veeva’s purpose-built life sciences software, as top biopharma firms increasingly standardize on its offerings.
• We'll explore how leading biopharma adoption of Vault CRM could shape Veeva's growth outlook and reinforce its competitive position.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Veeva Systems Investment Narrative Recap

At its core, investing in Veeva Systems means believing that the digital transformation of the life sciences industry will continue to accelerate, with top biopharma companies increasingly adopting cloud-based, industry-specific platforms for commercial operations. The recent wave of Vault CRM adoption by market leaders such as Bristol Myers Squibb and Merck reinforces Veeva’s competitive moat, but it does not materially change the central catalysts or the key risk: ongoing customer concentration and the power of large pharma clients remain areas to watch. Among recent developments, the commitment from Gilead Sciences to Veeva Vault CRM with integrated AI agents is particularly relevant. This move spotlights how leading firms are leveraging Veeva’s expanding set of AI-enabled products to drive commercial efficiency and workflow automation, supporting the narrative that broader adoption could increase platform stickiness and future revenue potential. However, it’s important for investors to contrast this progress with the fact that growing dependence on a handful of major customers exposes Veeva to potential shifts in...

Read the full narrative on Veeva Systems (it's free!)

Veeva Systems' narrative projects $4.3 billion revenue and $1.3 billion earnings by 2028. This requires 12.8% yearly revenue growth and a $490 million earnings increase from $809.9 million today.

Uncover how Veeva Systems' forecasts yield a $316.71 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Six individual fair value opinions from the Simply Wall St Community set a range for Veeva between US$265.94 and US$316.71 per share. While many see upside, Veeva’s reliance on large pharma clients means shifts in customer behavior could impact results, so review this variety of perspectives before forming your own outlook.

Explore 6 other fair value estimates on Veeva Systems - why the stock might be worth 12% less than the current price!

Build Your Own Veeva Systems Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Veeva Systems research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com